Infliximab alleviates the mortality, mesenteric hypoperfusion, aortic dysfunction, and multiple organ damage in septic rats

Basit Öğe Kaydı
dc.contributor.authorOzer, Erdem Kamil
dc.contributor.authorGoktas, Mustafa Tugrul
dc.contributor.authorKilinc, Ibrahim
dc.contributor.authorToker, Aysun
dc.contributor.authorBariskaner, Hulagu
dc.contributor.authorUgurluoglu, Ceyhan
dc.contributor.authorIskit, Alper Bektas
dc.date.accessioned2024-02-23T14:26:14Z
dc.date.available2024-02-23T14:26:14Z
dc.date.issued2017
dc.departmentNEÜen_US
dc.description.abstractTumor necrosis factor-alpha (TNF-alpha) is a pivotal mediator that triggers inflammatory process, oxidative stress, and multiple organ injury in sepsis. We investigated the effects of infliximab on survival, mesenteric artery blood flow (MBF), vascular reactivity, and oxidative and inflammatory injuries in cecal ligation and puncture (CLP)-induced sepsis. Wistar rats were divided into Sham, CLP, Sham+infliximab, and CLP+infliximab subgroups. Twenty-four hours before the operations, rats were injected intraperitoneally with infliximab (7 mg/kg) or vehicle (saline; 1 mL/kg). Twenty hours after the operations, MBF and phenylephrine responses of isolated aortic rings were measured. Tissue damages were examined biochemically and histopathologically. Furthermore, survival rates were monitored throughout 96 h. Infliximab improved survival, mesenteric perfusion, and aortic function after CLP. Increases of serum AST, ALT, LDH, BUN, Cr, and inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6) induced by CLP were blocked by infliximab. Infliximab prevented malondialdehyde elevations in septic liver, lung, spleen, and kidney tissues, as well as glutathione reductions in septic liver, spleen, and kidney tissues. Protective effects of infliximab on multiple organ damage were also observed histopathologically. Infliximab showed protective effects in sepsis due to its improvement effects on mesenteric perfusion, aortic function, and its anti-inflammatory and antioxidative effects.en_US
dc.description.sponsorshipTurkish Academy of Sciences [EA-TUBA-GEBIP/2001-2-11]en_US
dc.description.sponsorshipAlper B. Iskit has been supported by the Turkish Academy of Sciences, in the framework of the Young Scientist Award Program (EA-TUBA-GEBIP/2001-2-11). This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.en_US
dc.identifier.doi10.1139/cjpp-2016-0628
dc.identifier.endpage872en_US
dc.identifier.issn0008-4212
dc.identifier.issn1205-7541
dc.identifier.issue7en_US
dc.identifier.pmid28459157en_US
dc.identifier.scopus2-s2.0-85021832326en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage866en_US
dc.identifier.urihttps://doi.org/10.1139/cjpp-2016-0628
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14116
dc.identifier.volume95en_US
dc.identifier.wosWOS:000404738500012en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherCanadian Science Publishingen_US
dc.relation.ispartofCanadian Journal Of Physiology And Pharmacologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectInfliximaben_US
dc.subjectSepsisen_US
dc.subjectSurvivalen_US
dc.subjectMultiple Organ Dysfunctionen_US
dc.subjectVascular Reactivityen_US
dc.subjectMesenteric Arterial Blood Flowen_US
dc.titleInfliximab alleviates the mortality, mesenteric hypoperfusion, aortic dysfunction, and multiple organ damage in septic ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu